Drug profile · INN
bimekizumab
BIMZELX
bimekizumab (BIMZELX) is a interleukin-17f inhibitor.
Drug details — bimekizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 12
- Data quality
- 0.83
Quick answer
bimekizumab (BIMZELX) is a interleukin-17f inhibitor.
Key facts
Mechanism of action
Interleukin-17F inhibitor
Primary target: Interleukin-17A
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape
UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.
UCB's Bimzelx Triumph: Psoriatic Arthritis Market Implications and Competitive Landscape
UCB's Bimzelx (bimekizumab) has secured significant approvals for psoriatic arthritis, demonstrating strong efficacy in head-to-head trials. This success reshapes the competitive landscape and presents key opportunities and challenges for pharmaceutical business development and investment.
UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis
UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.
Congress & event coverage
- PresentationEULAR 2026
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bimekizumab?
bimekizumab (BIMZELX) is a interleukin-17f inhibitor.
What is the brand name for bimekizumab?
BIMZELX is a marketed brand name for bimekizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.